Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
Xenon Pharmaceuticals Analyst Ratings
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk
Buy Rating Justified by Xenon Pharmaceuticals' Advanced Epilepsy Program and Growth Prospects in Neuroscience
Maintaining Buy Rating on Xenon Pharmaceuticals With a $60 Target Amidst XEN1101 Clinical Advancements
Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62
Xenon Pharmaceuticals Analyst Ratings
B of A Securities Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $56
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Analyst Ratings
Baird Initiates Coverage On Xenon Pharmaceuticals With Outperform Rating, Announces Price Target of $63
Xenon Pharmaceuticals Analyst Ratings
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56
Xenon Pharmaceuticals Analyst Ratings